INZY News and Press, Inozyme Pharma Inc. From 09/20/23

BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...

2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma  ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company&...

2023-08-29 04:24:41 ET Summary Inozyme Pharma specializes in rare diseases with INZ-701 as its lead product; faced a stock decline after INZ-701 updates. Company boasts strong financials; $140.2M assets (plus $64.5M from an August equity raise), >2 years of runway, positive INZ...

2023-08-08 14:22:05 ET Inozyme Pharma press release ( NASDAQ: INZY ): Q2 GAAP EPS of -$0.35 beats by $0.08 . Cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023. Based on its current plans, the Company now anticipates its cash...

2023-08-08 11:23:45 ET What Are Penny Stocks? Penny stocks are shares of companies trading for under $5. They generally are the stock of companies in early or development stages that are typically smaller in size. While the vast majority of penny stocks trade on the OTC market or &#...

2023-08-08 10:40:52 ET Inozyme Pharma press release ( NASDAQ: INZY ): Q2 GAAP EPS of -$0.35. Cash Position and Financial Guidance. Cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023. For further details see: Inozyme Pharma ...

– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pe...

2023-08-04 10:54:17 ET Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains. On any given day, you’ll likely see at least a few of these cheap sto...

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the closing of its underwritten public off...